返回 
加入收藏
我国罕见病药品价格水平和可负担性研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 我国罕见病药品价格水平和可负担性研究 |
| TITLE： | Study on the Price and Affordability of Rare Disease Drug s in Chin a |
| 摘要： | 目的：评估我国罕见病药品价格水平及可负担性情况，提出改善罕见病治疗药品可负担性的政策建议，以期为政府主管部门的相关决策提供依据。方法：基于《第一批罕见病目录》和《罕见病诊疗指南（2019年版）》选择罕见病药品，采用中位价格比值法（MPR）评估药品价格水平，用药品年治疗费用和城乡居民年均可支配收入的倍数评估药品可负担性以及价格管理政策对药品价格和可负担性的影响。结果与结论：共纳入罕见病药品71种，其MPR中位数为0.83，其中原研药的MPR中位数为1.13、仿制药的MPR中位数为0.37。71种罕见病药品年均费用相当于2020年我国城镇居民年均收入的0.001～178.43倍，农村居民年均收入的0.003～456.57倍，分别有21和28种药品年均费用超过城镇和农村居民年均收入。对其中14种罕见病药品实施医保准入谈判或集中带量采购后，相关药品的MPR中位数从1.71下降到0.46，费用超过城镇居民年收入的药品数由8种降为0种，农村居民由10种降为5种。总体上，我国罕见病药品价格水平略低于国际参考价格，但原研药价格水平整体高于国际参考价格，部分药品费用远超过居民支付能力。建议加强原研药价格管理，促进优质仿制药临床替代，建立健全高负担罕见病药品支付保障体系。 |
| ABSTRACT： | OBJECTIVE：To evaluate the price and affordability of rare disease drugs in China and provide the suggestions for the improvement of rare disease drug affordability in order to provide reference for the relevant decision-making of government departments. METHODS ：According to the List of the First Batch of Rare Diseasesand Diagnosis and Treatment Guideline for Rare Diseases（2019 edition），rare disease drugs were selected. The median price ratio （MPR）was used to evaluate the drug price level ， and the ratio of the annual drug costs to the annual disposable income of urban or rural residents was used to evaluate the affordability，and the impact of price management policieson drug prices and affordability. RESULTS and CONCLUSIONS ：A total of 71 kinds of rare disease drugs were included ，and the median MPR of them was 0.83；among them ，the median MPR of the original drugs was 1.13，and the median MPR of the generic drugs was 0.37. The annual cost of 71 rare disease drugs was 0.001-178.43 times the average annual income of urban residents ，and 0.003-456.57 times the average annual income of rural residents. There were 21 and 28 drugs whose annual cost exceeded the annual income of urban and rural residents.After the implementation of national medical insurance negotiation or volume based procurement of 14 drugs，the median MPR of these drugs decreased from 1.71 to 0.46. For urban residents ，the number of unaffordable drugs had been reduced from 8 to 0；for rural residents，it had been reduced from 10 to 5. In summary ，the price level of orphan drugs in China was slightly lower than international reference price ，but the price level of original drugs was higher than the international reference price ，and the cost of some drugs far exceeded the residents ’ability to pay. It is suggested that the government should strengthen the price management of original drugs ，promote the substitution of high-quality generic drugs for original drugs ，and improve the payment system for high-value rare disease drugs. |
| 期刊： | 2021年第32卷第08期 |
| 作者： | 朱楚玉，孙维阳，常峰，路云 |
| AUTHORS： | ZHU Chuyu ，SUN Weiyang ，CHANG Feng，LU Yun |
| 关键字： | 罕见病药品；药品价格；中位价格比；可负担性 |
| KEYWORDS： | Rare disease drugs ；Drug price ；Median price ratio ；Affordability |
| 阅读数： | 442 次 |
| 本月下载数： | 13 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
